Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients

Clinical Cancer Research

Volumn 16, Issue 9, 2010, Pages 2646-2655

  Besser, Michal J ^a   Shapira Frommer, Ronnie ^a   Treves, Avraham J ^a,b   Zippel, Dov ^a   Itzhaki, Orit ^a   Hershkovitz, Liat ^a   Levy, Daphna ^a   Kubi, Adva ^a   Hovav, Einat ^a   Chermoshniuk, Natalia ^a   Shalmon, Bruria ^a   Hardan, Izhar ^a   Catane, Raphael ^a   Markel, Gal ^a,c   Apter, Sara ^a   Ben Nun, Alon ^a   Kuchuk, Iryna ^a   Shimoni, Avichai ^a   Nagler, Arnon ^a   Schachter, Jacob ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b Sheba Cancer Research Center   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CISPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DACARBAZINE; FLUCONAZOLE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; PACLITAXEL;

ADOPTIVE TRANSFER; ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DIARRHEA; FEBRILE NEUTROPENIA; FEMALE; HERPES ZOSTER; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; KIDNEY FAILURE; LUNG CONGESTION; LYMPHOCYTE CULTURE; LYMPHOCYTE TRANSFER; MALE; MELANOMA; METASTASIS; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; AUTOIMMUNITY; CELLS, CULTURED; COMBINED MODALITY THERAPY; DIARRHEA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LENGTH OF STAY; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77951714425     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0041     Document Type: Article

References (22)

1. Tarhini AA, Agarwala SS. Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther 2006;19:19-25.
2. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012.
3. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000;Suppl 1:S11-4.
4. Rosenberg SA, Yang JA, Nicholas PR. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-915 (Pubitemid 39273730)
5. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009;21: 233-240
6. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8:299-308.
7. Dudley ME, Rosenberg SA. Adoptive cell transfer therapy. Semin Oncol 2007;34:524-531
8. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-2357
9. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008;26: 5233-5239
10. Besser MJ, Shapira-Frommer R, Treves AJ, et al. Minimally-cultured or selected autologous tumor infiltrating lymphocytes following a lymphodepleting chemotherapy regimen in metastatic melanoma patients. J Immunother 2009;32:415-423
11. Schwartzentruber DJ, Hom SS, Dadmarz R, et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol 1994;12:1475-1483
12. Aebersold P, Hyatt C, Johnson S, et al. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J Natl Cancer Inst 1991;83:932-937
13. Shen X, Zhou J, Hathcock KS, et al. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother 2007;30:123-129 (Pubitemid 46052211)
14. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 2005;75:7046-7052 (Pubitemid 41598952)
15. Robbins PF, Dudley ME, Wunderlich J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004;173:7125-7130 (Pubitemid 39628146)
16. Tran KQ, Zhou J, Durflinger KH, et al. Minimally cultured tumorinfiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother 2008;31:742-751
17. Powell DJ, Jr., Dudley ME, Robbins PF, Rosenberg SA. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 2005;105:241-250
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216
19. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003;26:332-342 (Pubitemid 36858717)
20. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992;257:238-241
21. Dudley ME, Ngo LT, Westwood J, Wunderlich JR, Rosenberg SA. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes. Cancer J Sci Am 2000;6:69-77. (Pubitemid 30469165)
22. Schallmach E, Sareli R, Besser MJ, et al. Collection of largescale expanded lymphocyte cultures for adoptive immunotherapy using a COBE spectra apheresis machine. J Immunother 2008; 31:563-568